clofibrate has been researched along with Blood Pressure, High in 51 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study examined whether long-term induction of renal fatty acid omega-hydroxylase with clofibrate would alter the development of hypertension in Dahl SS/Jr rats." | 7.68 | Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. ( Frohlich, B; Ma, YH; Markham, B; Roman, RJ, 1993) |
| "Clofibrate prevented the increase in SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels." | 5.37 | Effects of clofibrate on salt loading-induced hypertension in rats. ( Cruz, A; Moreno, JM; Osuna, A; Pérez-Abud, R; Quesada, A; Rodríguez-Gómez, I; Vargas, MÁ; Wangensteen, R, 2011) |
| " Therefore, our aim was to study whether clofibrate-induced peroxisome proliferator-activated receptor-alpha (PPAR-α) stimulation is able to prevent alterations in cardiac functioning derived from RAS overstimulation in the left ventricle of rats with hypertension secondary to aortic coarctation and to improve antioxidant defenses." | 3.83 | Peroxisome proliferator-activated receptor-α stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle. ( Cervantes-Pérez, LG; Del Valle-Mondragón, L; Ibarra-Lara, L; Oidor-Chan, VH; Pastelín-Hernández, GS; Pérez-Severiano, F; Ramírez-Ortega, M; Sánchez-Aguilar, M; Sánchez-Mendoza, A; Soria-Castro, E; Torres-Narváez, JC; Zarco-Olvera, G, 2016) |
| " Clofibrate treatment reduced SBP by 26%±2% and proteinuria by 43%±9% in SHR but not in WKY rats." | 3.80 | PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. ( Newaz, M; Yousefipour, Z, 2014) |
| "Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension in Dahl salt-sensitive (Dahl S) rats." | 3.70 | Effects of lipid-lowering agents in the Dahl salt-sensitive rat. ( Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998) |
| "Clofibrate has been reported to prevent the development of hypertension in Dahl S rats, but its mechanism of action remains to be determined." | 3.70 | Induction of P4504A activity improves pressure-natriuresis in Dahl S rats. ( Alonso-Galicia, M; Frohlich, B; Roman, RJ, 1998) |
| " The present study examined whether long-term induction of renal fatty acid omega-hydroxylase with clofibrate would alter the development of hypertension in Dahl SS/Jr rats." | 3.68 | Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. ( Frohlich, B; Ma, YH; Markham, B; Roman, RJ, 1993) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| " It is suggested that the liver lesions of this woman may be related to long-term administration of hypolipidemic drug clofibrate for hypercholesteremia and the lesions could be one of the precursor changes of human hepatocellular carcinoma." | 3.66 | Adenoma with multiple hyperplastic nodules in noncirrhotic liver possibly related to long-term administration of a hypolipidemic drug. ( Mori, H; Sugie, S; Takahashi, M; Tanaka, T, 1982) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Clofibrate prevented the increase in SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels." | 1.37 | Effects of clofibrate on salt loading-induced hypertension in rats. ( Cruz, A; Moreno, JM; Osuna, A; Pérez-Abud, R; Quesada, A; Rodríguez-Gómez, I; Vargas, MÁ; Wangensteen, R, 2011) |
| "Type V hyperlipemia is not very common." | 1.26 | [Type V hyperlipemia. 54 cases (author's transl)]. ( Beaumont, V; Buxtorf, JC; Jacotot, B; Schlesinger, M, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (66.67) | 18.7374 |
| 1990's | 3 (5.88) | 18.2507 |
| 2000's | 8 (15.69) | 29.6817 |
| 2010's | 6 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Yousefipour, Z | 1 |
| Newaz, M | 2 |
| Ibarra-Lara, L | 2 |
| Del Valle-Mondragón, L | 2 |
| Soria-Castro, E | 2 |
| Torres-Narváez, JC | 1 |
| Pérez-Severiano, F | 3 |
| Sánchez-Aguilar, M | 2 |
| Ramírez-Ortega, M | 1 |
| Cervantes-Pérez, LG | 3 |
| Pastelín-Hernández, GS | 2 |
| Oidor-Chan, VH | 1 |
| Zarco-Olvera, G | 1 |
| Sánchez-Mendoza, A | 2 |
| Zhou, Y | 2 |
| Luo, P | 1 |
| Chang, HH | 2 |
| Huang, H | 2 |
| Yang, T | 1 |
| Dong, Z | 1 |
| Wang, CY | 2 |
| Wang, MH | 3 |
| Ying, CJ | 1 |
| Noguchi, T | 1 |
| Aso, H | 1 |
| Ikeda, K | 1 |
| Yamori, Y | 1 |
| Nara, Y | 1 |
| Del Valle, L | 1 |
| Rubio-Ruíz, E | 1 |
| Martínez-Lazcano, JC | 1 |
| Gelosa, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Pignieri, A | 1 |
| Nobili, E | 1 |
| Castiglioni, L | 1 |
| Cimino, M | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Cruz, A | 1 |
| Rodríguez-Gómez, I | 1 |
| Pérez-Abud, R | 1 |
| Vargas, MÁ | 1 |
| Wangensteen, R | 1 |
| Quesada, A | 1 |
| Osuna, A | 1 |
| Moreno, JM | 1 |
| Ibarra-Lara, Mde L | 1 |
| Escalante, B | 1 |
| Vargas-Robles, H | 1 |
| Pastelín, G | 1 |
| Sánchez-Mendoza, MA | 1 |
| Williams, JM | 1 |
| Zhao, X | 1 |
| Imig, JD | 1 |
| Pollock, DM | 1 |
| Blanton, A | 1 |
| Fidelis, P | 1 |
| Oyekan, A | 1 |
| Du, J | 1 |
| Wu, JF | 1 |
| Sankaralingam, S | 1 |
| Desai, KM | 1 |
| Wilson, TW | 2 |
| Oliver, MF | 5 |
| Marshall, AJ | 1 |
| Mori, H | 1 |
| Tanaka, T | 1 |
| Sugie, S | 1 |
| Takahashi, M | 1 |
| Bock, KD | 1 |
| Rose, G | 1 |
| Akhmeteli, MA | 1 |
| Kazakov, IuM | 1 |
| Chaialo, PP | 1 |
| Tokar', AV | 1 |
| Rudaia, ES | 1 |
| Roman, RJ | 3 |
| Ma, YH | 1 |
| Frohlich, B | 2 |
| Markham, B | 1 |
| Alonso-Galicia, M | 2 |
| Idzior-Waluś, B | 1 |
| Mono, G | 1 |
| Kuhn, E | 1 |
| Schlesinger, M | 1 |
| Jacotot, B | 1 |
| Beaumont, V | 1 |
| Buxtorf, JC | 1 |
| Basta, LL | 1 |
| Williams, C | 1 |
| Kioschos, JM | 1 |
| Spector, AA | 1 |
| Rumpf, KW | 1 |
| Quellhrost, E | 1 |
| Scheler, F | 1 |
| Parsons, WB | 1 |
| Santrůcek, M | 1 |
| Geizerová, H | 1 |
| Hejl, Z | 1 |
| Grafnetter, D | 1 |
| Green, KG | 1 |
| Heady, A | 1 |
| Borhani, NO | 1 |
| Miettinen, TA | 2 |
| Huttunen, JK | 1 |
| Naukkarinen, V | 1 |
| Strandberg, T | 1 |
| Vanhanen, H | 1 |
| Murata, Y | 1 |
| Tani, M | 1 |
| Amano, M | 1 |
| Menotti, A | 1 |
| Puddu, V | 1 |
| Porcellati, G | 1 |
| Valcavi, U | 1 |
| Gaiti, A | 1 |
| Albeaux-Fernet, M | 1 |
| Gelinet, M | 1 |
| Deribreux, J | 1 |
| Saheta, NP | 1 |
| Neugebauer, A | 1 |
| Trenckmann, H | 1 |
| Duck, HJ | 1 |
| Fleischmann, HJ | 1 |
| Schauer, J | 1 |
| Begg, TB | 1 |
| Likoff, W | 1 |
| Takayasu, K | 1 |
| Tada, T | 1 |
| Okada, F | 1 |
| Yoshikawa, I | 1 |
| Nakano, M | 1 |
| Nakamura, Y | 1 |
| Fejfar, Z | 1 |
| Vanĕcek, R | 1 |
| Harrold, BP | 1 |
8 reviews available for clofibrate and Blood Pressure, High
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Strategy of reducing coronary risk and the use of drugs.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Cerebrovascular Disorders; Cholesterol; Clofibra | 1984 |
Drug therapy of hypertension and ischaemic heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Antihypertensive Agents; Aspirin; Clofibrate; C | 1981 |
[Prevention of cardiovascular diseases].
Topics: Adult; Arteriosclerosis; Blood Pressure; Cholesterol; Clofibrate; Coronary Disease; Humans; Hyperten | 1982 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
[Cardiotoxic effects of drugs and various other substances. A review].
Topics: Adrenergic Agonists; Amphetamine; Antimony; Arrhythmias, Cardiac; Arsenic Poisoning; Catecholamines; | 1978 |
Iatrogenic cardiovascular disease (an aspect of preventive cardiology).
Topics: Abnormalities, Drug-Induced; Analgesics; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antidepressi | 1968 |
[Drug prevention of coronary disease].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Cholestyramine Resin; Clofibrate; Coronary Diseas | 1972 |
5 trials available for clofibrate and Blood Pressure, High
| Article | Year |
|---|---|
Cholesterol, coronaries, clofibrate and death.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Death, Sudden; Humans; H | 1978 |
Long-term use of probucol in the multifactorial primary prevention of vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cerebrovascular Disorders; Cholesterol, HDL; C | 1986 |
Prevention of coronary heart disease--propaganda, promises, problems, and prospects.
Topics: Adult; Arteriosclerosis; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet; | 1986 |
Strategy, yield and risks of controlling plasma lipids in the primary prevention of coronary heart disease.
Topics: Adult; Arteriosclerosis; Cholesterol; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet; | 1985 |
General therapeutic and prophylactic problems in the treatment of atherosclerosis.
Topics: Aged; Arteriosclerosis; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diet Therapy; Dietar | 1972 |
38 other studies available for clofibrate and Blood Pressure, High
| Article | Year |
|---|---|
PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Clofibrate; Disease Models, Ani | 2014 |
Peroxisome proliferator-activated receptor-α stimulation by clofibrate favors an antioxidant and vasodilator environment in a stressed left ventricle.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Antioxidants; Aortic Coarct | 2016 |
Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Desoxycorticosterone; Hydroxyeicosatetr | 2008 |
The role of cytochrome p-450 in salt-sensitive stroke in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Anticholesteremic Agents; Arterioles; Aryl Hydrocarbon Hydroxylases; Blood Pressure; Cerebr | 2008 |
PPARalpha stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner.
Topics: Angiotensin II; Animals; Antioxidants; Aortic Coarctation; Blood Pressure; Clofibrate; Gene Expressi | 2010 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Effects of clofibrate on salt loading-induced hypertension in rats.
Topics: Animals; Anticholesteremic Agents; Blood Pressure; Clofibrate; Heart Rate; Hypertension; Male; Rats; | 2011 |
Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension.
Topics: Animals; Biopterins; Clofibrate; Disease Models, Animal; GTP Cyclohydrolase; Hypertension; Hypolipid | 2012 |
Peroxisome proliferator-activated receptor-alpha activation reduces salt-dependent hypertension during chronic endothelin B receptor blockade.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Dose-Response Relationship, Drug; Drug | 2005 |
NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects.
Topics: Animals; Blood Pressure; Clofibrate; Desoxycorticosterone; Endothelin-1; Free Radicals; Hypertension | 2005 |
Induction of renal 20-hydroxyeicosatetraenoic acid by clofibrate attenuates high-fat diet-induced hypertension in rats.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Dietary Fats; Enzyme Induction; Hydroxy | 2006 |
Chronic clofibrate administration prevents saline-induced endothelial dysfunction and oxidative stress in young Sprague-Dawley rats.
Topics: Animals; Anions; Anticholesteremic Agents; Carbonates; Carotid Arteries; Clofibrate; Endothelium; Hy | 2008 |
Adenoma with multiple hyperplastic nodules in noncirrhotic liver possibly related to long-term administration of a hypolipidemic drug.
Topics: Aged; Carcinoma, Hepatocellular; Clofibrate; Female; Humans; Hypercholesterolemia; Hyperplasia; Hype | 1982 |
[Benefit-risk evaluation in the physician's therapy decisions].
Topics: Clofibrate; Decision Making; Hypertension; Patient Care Planning; Risk | 1980 |
Strategy of prevention: lessons from cardiovascular disease.
Topics: Adult; Aged; Cholesterol; Cholesterol, Dietary; Clofibrate; Contraceptives, Oral; Coronary Disease; | 1981 |
[Blood viscosity and hematocrit indices in arteriosclerosis].
Topics: Adolescent; Adult; Arteriosclerosis; Blood Viscosity; Clofibrate; Coronary Disease; Hematocrit; Huma | 1981 |
[Comparative evaluation of the hypolipidemic effect of cetamiphen, polysponin and miscleron in middle-aged and elderly patients with hypertension].
Topics: Aged; Clofibrate; Drug Combinations; Humans; Hypertension; Hypolipidemic Agents; Middle Aged; Phenyl | 1980 |
Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats.
Topics: Animals; Arachidonic Acid; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzy | 1993 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sy | 1998 |
Induction of P4504A activity improves pressure-natriuresis in Dahl S rats.
Topics: Animals; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Diet, S | 1998 |
[Type V hyperlipemia. 54 cases (author's transl)].
Topics: Adolescent; Adult; Aged; Alcoholism; Blood Protein Electrophoresis; Child; Child, Preschool; Cholest | 1979 |
Regression of atherosclerotic stenosing lesions of the renal arteries and spontaneous cure of systemic hypertension through control of hyperlipidemia.
Topics: Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Female; Humans; Hyperlipidemias; Hy | 1976 |
[Diabetic nephropathy, hypothyroidism and colfibrate-induced myopathy (author's transl)].
Topics: Adult; Clofibrate; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabet | 1976 |
Hyperlipidemia: to treat or not to treat.
Topics: Cerebrovascular Disorders; Cholestyramine Resin; Clofibrate; Coronary Disease; Female; Humans; Hyper | 1975 |
[Experiences of 15 years in the screening of ischaemic heart diseases and arterial hypertension].
Topics: Cholesterol; Clofibrate; Coronary Disease; Czechoslovakia; Humans; Hypertension; Male; Middle Aged; | 1975 |
Blood pressure, cigarette smoking and heart attack in the WHO co-operative trial of clofibrate.
Topics: Bezafibrate; Clofibrate; Coronary Disease; Fibrinogen; Humans; Hypertension; Male; Smoking; World He | 1989 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
Erythema multiforme due to clofibrate.
Topics: Aged; Clofibrate; Erythema Multiforme; Female; Humans; Hyperlipidemias; Hypertension | 1988 |
[Short-term pilot study of the feasibility of multifactor reduction of coronary risk].
Topics: Adult; Arteriosclerosis; Clofibrate; Clopamide; Coronary Disease; Diet Therapy; Dietary Fats; Ergolo | 1973 |
When a drug is the culprit.
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Clofibrate; Depression; Drug-Related Side Effect | 1973 |
[Biochemical changes in atherosclerosis: current concepts and experimental applications].
Topics: Animals; Arteriosclerosis; Blood Coagulation Disorders; Blood Vessels; Butyrates; Cholesterol; Clofi | 1971 |
[Sheehan's disease followed by severe arterial hypertension with right renal artery stenosis. Discussion of the role of hypopituitarism in atherogenesis].
Topics: Adrenal Cortex Hormones; Adult; Androgens; Arteriosclerosis; Clofibrate; Coronary Disease; Female; H | 1973 |
[Diagnosis and treatment of risk factors in chronic ischemic heart disease].
Topics: Adult; Age Factors; Arteriosclerosis; Cholestyramine Resin; Chronic Disease; Clofibrate; Coronary Di | 1974 |
Symposium on arteriosclerotic heart disease. Medical management of angina pectoris.
Topics: Acute Disease; Angina Pectoris; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Die | 1972 |
Human plasma fatty acid composition: the features of hyperlipoproteinemia and the influence of -linolenate and clofibrate.
Topics: Adult; Aged; Blood Protein Disorders; Cholesterol; Clofibrate; Diabetes Mellitus; Fatty Acids; Fatty | 1971 |
[Hyperlipiemia and its therapy by clofibrate].
Topics: Administration, Oral; Adult; Aged; Cholesterol; Clofibrate; Fatty Acids, Nonesterified; Female; Huma | 1969 |
Prevention of ischaemic heart disease. Possibilities and problems.
Topics: Adult; Age Factors; Aged; Cholesterol; Clofibrate; Coronary Disease; Czechoslovakia; Diet; Female; H | 1970 |
Diabetic retinopathy and hypertension.
Topics: Adult; Aged; Arteriosclerosis; Blood Pressure; Clofibrate; Diabetic Retinopathy; Exudates and Transu | 1971 |